The Federal Trade Commission said the deal would enable Amgen to “entrench” the monopoly positions of two Horizon drugs that lack competition. Read this story
The Federal Trade Commission said the deal would enable Amgen to “entrench” the monopoly positions of two Horizon drugs that lack competition. Read this story
More from The New York Times | Amgen,Pharmaceuticals prescription drugs,Mergers and Acquisitions,Lawsuits,Amgen Inc,Drugs (Pharmaceuticals),Mergers, Acquisitions and Divestitures,Suits and Litigation (Civil)